Skip to main content

Where are they now?: Oct 1, 2002


In Genome Technology last October, our cover story looked at the changing image of Affymetrix and how the microarray heavyweight was hoping to keep its corner on the market. A year later, the company, which plans to stay in the expression business as it expands its reach into genotyping, has announced increases in sales over the past year. Revenues for 2002 have also been higher than expected. And it seems that the image campaign has been working: Affymetrix was chosen as the 2002 GT All-Star for Company of the Year, and both president Sue Siegel and CEO Stephen Fodor were nominated for the All-Stars as well (see p. 51). Siegel was a runner-up for Person of the Year, and Fodor won his category for Most Masterful in Microarrays.

Also in last year’s issue was our annual Freeloaders’ Guide to GSAC, which we included in the September issue this year because the conference was moved up to the beginning of October (perhaps in a nod to the frosty Boston climate?).

And in a strange coincidence, two completely separate articles in the October issue wound up very much linked a year later. One was a brief story on the use of sequencing technology and bioinformatics techniques to identify the badly decomposed and mutilated remains found in mass graves in Sarajevo. The other was our Wild Type, featuring Gene Codes’ president Howard Cash. By the time the October 2001 issue hit your desk, Cash’s company was working on new software to help identify and track the remains found at the World Trade Center site. Because of that work, which entailed launching Gene Codes Forensics and making countless trips to New York City, Cash was selected by voters as this year’s GT All-Star Person of the Year (see p. 68).


The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.